Literature DB >> 7299612

Therapy of anisometropic amblyopia.

J D Kivlin, J T Flynn.   

Abstract

In 67 patients with strictly anisometropic amblyopia, we found statistically significant correlations among three measurable parameters: the vision before treatment, the amount of anisometropia and the vision after treatment. The predetermined factors associated with success of treatment were 1) lower amounts of anisometropia, particularly less than six diopters for myopes, 2) better initial vision, and 3) a younger patient for hyperopic differences. Patients with less than three diopters of anisometropia were more likely to succeed with the use of glasses alone and a trial of glasses did not prolong therapy time. Despite a substantial number of older patients with extreme amounts of anisometropia or very poor vision, the group as a whole did well with 70% achieving 20/40 or better. Thus therapy should be approached enthusiastically, even for highly myopic patients since other authors have reported success with them. The factors under the control of the ophthalmologist which will promote success in these patients are correct glasses prescriptions, particularly with full astigmatic correction, continued use of glasses as maintenance therapy, and patience, since these children required a median of eight months for therapy to be successful.

Entities:  

Mesh:

Year:  1981        PMID: 7299612     DOI: 10.3928/0191-3913-19810901-12

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  20 in total

1.  The association between anisometropia, amblyopia, and binocularity in the absence of strabismus.

Authors:  D R Weakley
Journal:  Trans Am Ophthalmol Soc       Date:  1999

2.  A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children.

Authors:  David K Wallace; Allison R Edwards; Susan A Cotter; Roy W Beck; Robert W Arnold; William F Astle; Carmen N Barnhardt; Eileen E Birch; Sean P Donahue; Donald F Everett; Joost Felius; Jonathan M Holmes; Raymond T Kraker; Michele Melia; Michael X Repka; Nicholas A Sala; David I Silbert; Katherine K Weise
Journal:  Ophthalmology       Date:  2006-06       Impact factor: 12.079

3.  Treatment of anisometropic amblyopia in children with refractive correction.

Authors:  Susan A Cotter; Allison R Edwards; David K Wallace; Roy W Beck; Robert W Arnold; William F Astle; Carmen N Barnhardt; Eileen E Birch; Sean P Donahue; Donald F Everett; Joost Felius; Jonathan M Holmes; Raymond T Kraker; Michele Melia; Michael X Repka; Nicholas A Sala; David I Silbert; Katherine K Weise
Journal:  Ophthalmology       Date:  2006-06       Impact factor: 12.079

4.  The effect of amblyopia therapy on ocular alignment.

Authors:  Michael X Repka; Jonathan M Holmes; B Michele Melia; Roy W Beck; Matthew D Gearinger; Susanna M Tamkins; David T Wheeler
Journal:  J AAPOS       Date:  2005-12       Impact factor: 1.220

5.  Monocular and binocular reading performance in children with microstrabismic amblyopia.

Authors:  E Stifter; G Burggasser; E Hirmann; A Thaler; W Radner
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

6.  Photorefractive keratectomy for anisometropic amblyopia in children.

Authors:  Evelyn A Paysse
Journal:  Trans Am Ophthalmol Soc       Date:  2004

7.  Anisometropia in children: analysis of a hospital population.

Authors:  J de Vries
Journal:  Br J Ophthalmol       Date:  1985-07       Impact factor: 4.638

8.  Design of the Monitored Occlusion Treatment of Amblyopia Study (MOTAS).

Authors:  C E Stewart; A R Fielder; D A Stephens; M J Moseley
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

9.  Practical management of amblyopia.

Authors:  G K von Noorden
Journal:  Int Ophthalmol       Date:  1983-01       Impact factor: 2.031

Review 10.  The relationship between anisometropia and amblyopia.

Authors:  Brendan T Barrett; Arthur Bradley; T Rowan Candy
Journal:  Prog Retin Eye Res       Date:  2013-06-15       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.